Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Growth Potential: How Will Market Size Shift Through 2030?
The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing sector has experienced robust growth recently. This market is anticipated to expand from $2.89 billion in 2025 to $3.1 billion in 2026, with a compound annual growth rate (CAGR) of 7.3%. The historical expansion can be linked to several factors, such as a limited number of specialized peptide API manufacturers, the rising demand for peptide therapeutics, pharmaceutical companies’ reliance on in-house synthesis, regulatory compliance necessities, and an increase in preclinical and clinical trials.
The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market is projected to experience robust expansion over the coming years. It is anticipated to reach $4.11 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. This anticipated growth during the forecast period is propelled by factors such as the enhancement of contract manufacturing organization (CMO) capabilities for peptide API, increased capital allocation towards advanced peptide synthesis technologies, the emergence of personalized medicine and biologics, a surge in outsourcing activities from smaller and medium-sized pharmaceutical firms, and the integration of digital manufacturing and AI-driven process optimization. Key developments shaping the forecast period encompass an escalating need for contract manufacturing of peptide APIs, a heightened emphasis on GMP-grade production standards and adherence, an increase in outsourced peptide synthesis for clinical trial purposes, the broadening of process optimization and technology transfer services, and the implementation of custom peptide synthesis tailored for personalized therapeutics.
Get A Free Sample Report With In-Depth Market Insights:
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Demand Drivers: What’s Powering Industry Growth?
The increasing incidence of diabetes is anticipated to drive expansion in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market. Diabetes is defined as a persistent metabolic condition characterized by high blood glucose (sugar) levels stemming from the body’s inadequate insulin creation or its impaired capacity to utilize insulin. The growing occurrence of diabetes is largely driven by rising obesity rates, as surplus body fat fosters insulin resistance and interferes with blood sugar regulation. Peptide therapeutics utilize contract API manufacturing for the mass production of drugs that mimic hormones, thereby improving insulin release and glucose management in the context of diabetes. As an example, a report released in March 2025 by the Office for Health Improvement and Disparities, a UK government department, noted that the prevalence of type 2 diabetes among adults aged 17 and above in England stood at 7.0% in March 2024, an increase from 6.8% in March 2023. Consequently, the expanding prevalence of diabetes is a significant driver for the growth of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market.
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Segment Landscape And Growth Outlook
The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market covered in this report is segmented –
1) By Scale Of Operation: Preclinical Or Clinical, Commercial
2) By Synthesis Method: Non Chemical Synthesis, Chemical Synthesis
3) By Enterprise Type: Large Enterprise, Small And Medium Enterprises
Subsegments:
1) By Preclinical Or Clinical: Discovery And Preclinical Development, Phase II Or III Manufacturing, Phase I Manufacturing
2) By Commercial: Commercial-Scale Good Manufacturing Practice Manufacturing, Tech Transfer And Scale-up, Lifecycle Management Or Process Optimization
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing sector are concentrating on creating novel approaches, such as the continuous flow synthesis platform, to optimize production and address increasing complexity in pharmaceutical development. This continuous flow synthesis platform integrates multiple stages, including reaction, separation, concentration, and crystallization, into a single, uninterrupted process with real-time in-line measurement, enabling precise, non-destructive monitoring and effective scalability. For instance, in May 2023, SynCrest Inc., a Japan-based contract research, development, and manufacturing organization (CRDMO), announced the launch of its good manufacturing practice (GMP)-compliant Naruto Plant, which is equipped with a continuous flow synthesis platform for peptide and nucleotide API production. This platform facilitates the rapid and high-quality manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, significantly reducing lead times and production costs. This innovation is effectively meeting the growing market demand for advanced peptide-based therapeutics by offering scalable, efficient, and cost-effective API manufacturing solutions.
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., BCN Peptides S.A.
View The Full Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Report:
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model